CMVLF Stock News Cellectis Romainvil (CMVLF) 17.1420 07/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cellectis Romainvil (CMVLF) 17.1420 $CMVLF

Cellectis R&D / Analyst Day
Business Wire - Wed Jun 25, 11:18AM CDT
Regulatory News:

Biotech Funding Deals and Partnerships 2014: Analysis of 56 Recent Venture Capital and Corporate Capital Funding and Other Transactions
M2 - Wed Jun 25, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r6b8dm/biotech_funding) has announced the addition of the "Biotech Funding Deals and Partnerships: Analysis of Recent Venture Capital and Corporate Capital Funding and Other Transactions" report to their offering. Nearly one out of every 8 dollars invested in companies are invested in biotech. Biotech investment has increased significantly in the past few years, and 2013 saw a notable spike. In the last few years, this has resulted in a complex series of deals and transactions, ranging from complete buyouts, to licensing transactions, to a variety of collaborative arrangements. In addition to this influx of corporate capital, biotechnology companies have seen a significant influx of venture capital, as investors invest in new science and technology that they believe have potential in the clinic. Recent Biotech Funding Deals and Partnerships, attempts to provide clarity on the phenomenon. The report analyzes the recent, current and potential landscape for investing in the biotechnology sector. Included in the report's coverage are the following data points - 56 Key Biotech Deals Analyzed: Financial Details and Therapeutic Potential - Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013 (in US billions) - Health Care as a Percentage of Total Venture Investment, 2009-2012 (in US billions) - Biotech Companies Raising Series A Dollars, 2009-2012, Greater than $2 Million - Number of Biotech Series A Companies by Indication Oncology, - Platform Discovery, Diagnostics, CNS, Autoimmune) - Biotech Total Deal Value, 2005-2012 - IPO Statistics - Personalized Medicine Disclosed M&A Number of Deals by Focus, 2010-2013 Analyzed are both venture and corporate capital funding efforts. In addition, the report looks at other collaborative approaches, including licensing, joint ventures and partnerships aimed at moving product candidates into the market place as approved therapies, especially if they address unmet medical needs. This report also reviews the nature and direction of funding trends, and reviews the important role that investments play in moving technology into the market place. The report profiles several biotechnology sector companies and the deals that they were involved in from 2011 to 2014. Some of the companies and transactions profiled in the report include: Alkermes, Boston Biomedical, Dicerna Pharmaceuticals, immatics biotechnologies, Micromet, Reata Pharmaceuticals, UCB and Xoma. The following are among the companies covered in this report: - Abbott - AC Immune SA - Adimab - Aileron Therapeutics Inc. - Atara Biotherapeutics - Cellectis - Clarus Ventures - CoStim Pharmaceuticals - Covagen AG - Dicerna Pharmaceuticals Inc. - Editas Medicine - Enanta Pharmaceuticals Inc. - Endocyte Inc. - Mannkind Corp. - Melinta Therapeutics - Micromet - Novartis - OncoMed - Onyx Pharmaceuticals Inc. - Otonomy Inc. - Pharmasset - Seattle Genetics Inc. - Royalty Pharma - Roche - Sutro Biopharma Inc. - Thesan Pharmaceuticals Inc. - UCB Inc. - Voyager Therapeutics - Xenon Pharmaceuticals Inc. - Xoma Corp. For more information visit http://www.researchandmarkets.com/research/r6...ch_funding

Cellectis' UCART19 Receives Advanced-Therapy Medicinal Product Classification from EMA
Business Wire - Mon Jun 23, 11:14AM CDT
Regulatory News :

Cellectis To Participate in the Piper Jaffray GenomeRx Symposium on June 23, 2014
Business Wire - Thu Jun 19, 11:00AM CDT
Dr. David Sourdive, PhD, EVP Corporate Development at Cellectis (Paris:ALCLS) (Alternext: ALCLS.PA) will be attending Piper Jaffray GenomeRx Symposium on Monday, June 23, 2014 in The Yale Club, New York.

Pfizer And Cellectis Enter Into Global Strategic Cancer Immunotherapy Collaboration
Business Wire - Wed Jun 18, 12:00AM CDT
Pfizer Inc. (NYSE FE) and Cellectis (Paris:ALCLS) today announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets. Cellectis' CAR-T platform technology provides a proprietary, allogeneic approach (utilizing engineered T-cells from a single donor for use in multiple patients) to developing CAR-T therapies that is distinct from other autologous approaches (engineering a patient's own T-cells to target tumor cells).

Cellectis to Present New Data Update on Its Allogeneic CAR T Cell Therapeutics at the 19th Congress of the European Hematology Association (EHA)
Business Wire - Tue Jun 10, 11:00AM CDT
Dr. Julianne Smith, PhD, VP CART Development at Cellectis (Paris:ALCLS) and Dr. Roman Galetto, PhD, Project Leader, will be attending the 19th Congress of the European Hematology Association in Milan, Italy from June 12th to 15th, 2014.

Cellectis enters into an agreement with CELLforCURE for the cGMP manufacturing of allogeneic CART cells
Business Wire - Mon Jun 09, 11:08AM CDT
Regulatory News:

Cellectis and Accelera (Nerviano Medical Sciences Group) Sign an Agreement to Complete Preclinical Studies of Cellectis' Lead Product Candidate UCART19
Business Wire - Thu Jun 05, 11:00AM CDT
Regulatory News:

Cellectis and Thermo Fisher Scientific Enter Into Agreements on TALEN(TM), a Leading Gene Editing Technology
Business Wire - Thu Jun 05, 1:00AM CDT
Regulatory News:

Cellectis plant sciences reports improvement of oil content in algae
Business Wire - Thu May 29, 11:00AM CDT
Regulatory News:

Cellectis will be Present at the ASCO Annual Meeting
PR Newswire - Tue May 27, 11:00AM CDT
André Choulika, PhD, CEO of Cellectis (Alternext: ALCLS) and Mathieu Simon, MD, Executive Vice President will be attending this year's ASCO meeting in Chicago, IL on May the 30th to June 3rd, 2014.

Cellectis Plant Sciences Reports Generation of High Oleic Soybean in Journal of Plant Biotechnology
Business Wire - Fri May 23, 11:40AM CDT
Regulatory News:

TAL-effector Nuclease: The USPTO Issues a Fourth Patent Licensed to Cellectis
Business Wire - Mon May 19, 11:30AM CDT
Regulatory News:

Cellectis Announces the Closing of EUR20.5 M Share Capital Increase Subscribed on March 24, 2014 by U.S. Biotechnology Specialist Institutional Investors
Business Wire - Mon Mar 31, 1:31PM CDT
Regulatory News:

Cellectis and Servier announce collaboration in allogeneic cell therapy: UCART19 to treat leukemia and 5 product candidates targeting solid tumors
Business Wire - Mon Feb 17, 1:03PM CST
Regulatory News:

US Patent Institutions Recognize the Patentability of Institut Pasteur/Cellectis Early Inventions on Meganucleases
Business Wire - Wed Feb 05, 11:00AM CST
Regulatory News:

Cellectis grants genOway an exclusive sublicense for its homologous recombination technology in the field of genetically modified rodent models
Business Wire - Tue Feb 04, 11:44AM CST
Regulatory News:

Cellectis Plant Sciences and Bayer CropScience Extend Their Partnership to Improve Crops by Gene Editing
Business Wire - Thu Jan 30, 12:00AM CST
Regulatory News:

Axxam and Cellectis Bioresearch Announce Their Collaboration to Offer a New Generation of Cell Based Assays
Business Wire - Fri Jan 17, 11:00AM CST
Regulatory News:

Cellectis Plant Sciences Announce the Finalization of the First Glycosylation Lines of Their Program
Business Wire - Thu Jan 09, 10:59AM CST
Regulatory News :
Scroll down for more posts ▼

Top 10 Most Recent News Articles

SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 92

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading
Ridgeline’s Dome Roof Award Signals Durable Craft Demand

Updated Category News Views 11

A faceted dome in the Alabama woods is about as far from a cookie-cutter reroof as it gets. Ridgeline Roofing & Restoration’s 2026 Excellence Award from Brava Roof Tile matters because the job in Pell City demanded the sort of painstaking field execution that separates a capable contractor from a crew merely moving shingles fast. Geometry Is Where Easy Claims Go to Die...

Continue Reading
Halff Elevates People and Delivery Leadership Team

Updated Category News Views 43

Infrastructure outfits rarely make much noise when they reshuffle leadership, but Halff’s Nov. 18 announcement deserves a closer look than the usual executive-title confetti. The employee-owned consulting firm has put Greg Carpenter in the chief people officer seat and named Leigh Hollis chief delivery officer. One role is aimed squarely at the human machinery; the...

Continue Reading
Fall Pest Risks Linger as Mild Weather Extends Threat

Updated Category News Views 16

A cold snap is not a magic off switch for mosquitoes, ticks, or rodents, and that is the sober point behind the National Pest Management Association's fall and winter 2026 Public Health Pest Index. The group is flagging conditions, not predicting that every household in a named city will face an infestation or illness. Still, mild temperatures, rain, flooding, and plenty...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 234

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Polsen Flex Deal Puts Pre-Tax Funds Behind Wearables

Updated Category News Views 114

A pile of soon-to-expire FSA cash is a peculiar sales catalyst, but Polsen Health has found one. The Amsterdam-based preventative-health wearable company is partnering with Flex to let customers pay for every Polsen watch and strap using eligible HSA or FSA funds at checkout. No reimbursement chase, no claim forms, and buyers can split the cost with another card. For a...

Continue Reading
Microsoft-Intel Azure Pact Puts Systems Work First

Updated Category News Views 18

Azure’s next bottleneck may be the plumbing between chips, not the chips alone. Microsoft and Intel announced on Nov. 18, 2026, a long-term expansion of their already ancient partnership aimed at shaping select pieces of Azure infrastructure for cloud and AI demand. That sounds dry, because infrastructure announcements usually do. But this one deserves a closer look: it...

Continue Reading
A €18 Million Mecca Chandelier Tests Austrian Craft

Updated Category News Views 134

Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...

Continue Reading
Redseer's $5M Bet on Faster MENA Decision Intelligence

Updated Category News Views 65

Speed has become the expensive commodity in Middle Eastern commerce, and Redseer is putting roughly $5 million behind the idea that executives will pay to get it. Its newly launched Benchmarks MENA 2.0 platform combines proprietary market data with strategic advisory across nine MENA markets. That sounds like another corporate dashboard pitch until you consider the target...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 180

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading

Top 5 Most Recently Viewed Articles

Symbotic Inc. Faces Legal Challenges Amid Financial Irregularities

Updated Category News Views 138

Symbotic Inc. Under Investigation for Securities Violations There has been a significant development for investors of Symbotic Inc. As concerns about the Company’s financial practices have arisen, the Schall Law Firm has initiated an investigation. This effort is aimed at ensuring shareholders are informed and protected amid allegations of misleading statements related...

Continue Reading
Turning Point Brands: Growth Opportunities Ahead with New Rating

Updated Category News Views 103

Turning Point Brands Gets a Positive Buy Rating Recently, Turning Point Brands (NYSE: TPB) earned a favorable Buy rating from Roth/MKM, along with a price target set at $50. This company is known for its wide range of consumer brands in the nicotine, tobacco, and cannabis markets, particularly recognized for its popular rolling papers and moist snuff products. Growth in...

Continue Reading
NeuroSense Therapeutics Celebrates Key Manufacturing Milestone

Updated Category News Views 232

NeuroSense Therapeutics Achieves Commercial Manufacturing Scale-Up NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a pioneering biotechnology firm dedicated to developing innovative treatments for severe neurodegenerative diseases, has announced a major milestone in its commercial journey. The company has successfully scaled up its production of PrimeC, preparing for...

Continue Reading
Discover the Potential of Azapeptides in Peptide Stability

Updated Category News Views 179

Unveiling the Future of Peptide Stability with Azapeptide Synthesis In this informative webinar, participants will discover how strategies involving azapeptides can significantly enhance the stability of peptides and improve workflows related to synthesis. Attendees will delve into techniques for incorporating aza-amino acids within peptides that utilize traditional amino...

Continue Reading
Ascent Solar Technologies Faces Major Challenges in Market

Updated Category News Views 118

Ascent Solar Technologies Hits 52-Week Low Ascent Solar Technologies, recognized for its cutting-edge thin-film photovoltaic modules, is currently going through a challenging period. The company's stock has reached a 52-week low of $2.32, reflecting an astonishing nearly 99.6% decline over the past year. This drastic drop underscores the significant hurdles the company...

Continue Reading